Drugs / AMPHORA
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00850837 | Feb 2009 → ? | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03243305 | Jul 2017 → Nov 2018 | — | Evofem Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01306331 | Apr 2011 → Jun 2014 | — | Evofem Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMPHORA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03243305 ↗ |
| Known as | Acidform Lubricant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00850837 ↗ |
| Known as | Phexxi | “Phexxi™ (Previously Referred to as AMPHORA®) Contraceptive Vaginal Gel” NCT03243305 ↗1“This vaginal gel is called Phexxi™ (previously known as Amphora)” NCT01306331 ↗ |
| Route | Other | “daily intravaginal applications of Acidform lubricant and HEC gel” NCT00850837 ↗ |